{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:43:27Z","timestamp":1787071407994,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Localized adverse events following mass drug administration for lymphatic filariasis elimination are often selflimiting. However, they are of significant concern to the participants and may affect community drug compliance if not managed appropriately. Here, we report a rather uncommon adverse event, the \u2018string sign\u2019 in a south Indian woman with bancroftian filarial infection treated with the triple drug regimen (IDA: ivermectin, diethylcarbamazine and albendazole). String sign is the manifestation of acute lymphangitis as a cordlike subcutaneous swelling due to the swollen and inflamed lymphatic vessel, which is believed to occur due to the death of the adult filarial worms subsequent to chemotherapy. Health care workers need to be aware of such unusual localized adverse events that may occur following MDA for LF elimination. Prompt medical management of adverse events and health education are important to ensure adherence to drug consumption during mass drug administration program.<\/jats:p>","DOI":"10.4103\/jvbd.jvbd_94_24","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T15:00:13Z","timestamp":1757689213000},"page":"143-145","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["\u201cString sign\u201d- acute lymphangitis in the forearm following triple drug therapy for bancroftian filarial infection"],"prefix":"10.4103","volume":"63","author":[{"given":"Vijesh Sreedhar","family":"Kuttiatt","sequence":"first","affiliation":[{"name":"ICMR-Vector Control Research Centre, Indira Nagar, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Rahi","sequence":"additional","affiliation":[{"name":"ICMR-Vector Control Research Centre, Indira Nagar, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jambulingam","family":"Purushothaman","sequence":"additional","affiliation":[{"name":"ICMR-Vector Control Research Centre, Indira Nagar, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"R1-20260302","first-page":"509","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2019","volume":"95","year":"2020","journal-title":"Weekly Epidemiol Rep"},{"issue":"4","key":"R2-20260302","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0035-9203(99)90140-2","article-title":"Acute attacks in the extremities of persons living in an area endemic for bancroftian filariasis: differentiation of two syndromes","volume":"93","author":"Dreyer","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"R3-20260302","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0035-9203(95)90666-5","article-title":"Episodic adenolymphangitis and lymphoedema in patients with bancroftian filariasis","volume":"89","author":"Pani","year":"1995","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R4-20260302","first-page":"301","article-title":"A preliminary study of filariasis related acute adenolymphangitis with special reference to precipitating factors and treatment modalities","volume":"26","author":"Shenoy","year":"1995","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"5","key":"R5-20260302","doi-asserted-by":"crossref","first-page":"e0006454","DOI":"10.1371\/journal.pntd.0006454","article-title":"Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature","volume":"12","author":"Budge","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"R6-20260302","doi-asserted-by":"crossref","first-page":"e1002839","DOI":"10.1371\/journal.pmed.1002839","article-title":"The safety of double-and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study","volume":"16","author":"Weil","year":"2019","journal-title":"PLoS Med"},{"issue":"2","key":"R7-20260302","doi-asserted-by":"crossref","first-page":"e0009069","DOI":"10.1371\/journal.pntd.0009069","article-title":"An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethyl-carbamazine plus albendazole for lymphatic filariasis in India","volume":"15","author":"Jambulingam","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"R8-20260302","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/00034983.1998.11813315","article-title":"Treatment of microfilaraemia in asymptomatic brugian filariasis: the efficacy and safety of the combination of single doses of ivermectin and diethylcarbamazine","volume":"92","author":"Shenoy","year":"1998","journal-title":"Ann Trop Med Parasitol"},{"issue":"3","key":"R9-20260302","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/00034983.1998.11813292","article-title":"The efficacy, tolerability and safety of diethylcarbamazine-fortified salt in the treatment of the microfilaraemias of brugian filariasis: an open, hospital-based study","volume":"92","author":"Shenoy","year":"1998","journal-title":"Ann Trop Med Parasitol"},{"issue":"1","key":"R10-20260302","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4269\/ajtmh.19-0532","article-title":"Frequency and clinical significance of localized adverse events following mass drug administration for lymphatic filariasis in an endemic area in South India","volume":"102","author":"Kuttiatt","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"R11-20260302","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/clinids\/7.3.341","article-title":"Efficacy of diethylcarbamazine in eradicating infection with lymphatic-dwelling filariae in humans","volume":"7","author":"Ottesen","year":"1985","journal-title":"Rev Infect Dis"},{"issue":"4","key":"R12-20260302","first-page":"312","article-title":"Epidemiological study on lymphatic filariasis in an endemic zone of Orissa","volume":"18","author":"Kar","year":"1986","journal-title":"J Commun Dis"},{"key":"R13-20260302","first-page":"270","article-title":"Atypical features in lymphatic filariasis","volume":"84","author":"Kar","year":"1986","journal-title":"Indian J Med Res"},{"issue":"5","key":"R14-20260302","doi-asserted-by":"crossref","first-page":"e0006454","DOI":"10.1371\/journal.pntd.0006454","article-title":"Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature","volume":"12","author":"Budge","year":"2018","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Journal of Vector Borne Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jvbd.jvbd_94_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:45:42Z","timestamp":1787067942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jvbd.jvbd_94_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jvbd.jvbd_94_24","relation":{},"ISSN":["0972-9062"],"issn-type":[{"value":"0972-9062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2024-05-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}